Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

The advent of the B.1.1.529 (Omicron) severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) variant, detected initially in Botswana and South Africa and now found in over 135 countries as of January 3, 2022, has sparked fears of a new global wave of infections and hospitalizations

3 Jan 2022

Production of molecular probes of spike and subdomains for all SARS-CoV-2 variants

Researchers designed molecular probes of diverse SARS-CoV-2 variants and evaluated their antibody binding specificity.

3 Jan 2022

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Researchers investigate the capacity of vaccine-induced antibodies to generate Fc-effector activity against the SARS-CoV-2 Omicron variant.

3 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.

3 Jan 2022

Minimal nAb titers against Omicron in the elderly after 3rd dose

Researchers measured titers of cross-protective neutralizing antibodies against SARS-CoV-2 after they had received a third booster dose.

3 Jan 2022

SARS-CoV-2 Omicron study on hamsters, shows virus results in a less severe disease

Researchers investigate the ability of immunity acquired from SARS-CoV-2 wild-type infection to protect against the Omicron variant in Syrian hamster models.

3 Jan 2022

NAbs activity against SARS-CoV-2 variants, including Omicron, in an elderly vaccinated cohort

Researchers investigate the neutralizing antibody activity against different variants of SARS-CoV-2 in fully immunized elderly individuals.

3 Jan 2022

Study shows structural and functional aspects of antibody neutralization of SARS-CoV-2 Omicron variant

Researchers investigated the potency of trimeric human nephrocystin SH3, TriSb92, a domain-derived antibody, against a conserved region in the receptor-binding domain (RBD) of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern.

31 Dec 2021

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

New findings indicate that TriSb92 is a potent inhibitor of SARS-CoV-2 infection targeting a conserved site in the RBD of the spike, which is insensitive for immune escape mutations found in the relevant variants of concern, including Omicron

31 Dec 2021

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

New evidence implies that the Omicron variant may cause a less severe and/or faster recovery from clinical COVID-19 disease.

31 Dec 2021

Omicron infection induces cross-reactive immune responses

New research revealed that vaccine-breakthrough infections might elicit cross-reactive bNAbs against all variants of concern.

31 Dec 2021

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.

31 Dec 2021

Vaccine-induced T-cells vs. Omicron well preserved compared with all variants

A team of international scientists has recently revealed that T cell responses induced by coronavirus disease 2019 (COVID-19) vaccines are able to cross-recognize different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is currently available on the bioRxiv* preprint server.

30 Dec 2021

The use of monoclonal antibodies against infectious pathogens

Joshua Tan of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health wrote a review article in the journal DNA and Cell Biology about the role of monoclonal antibodies and briefly described a study on bispecific antibodies that neutralize SARS-CoV-2.

30 Dec 2021

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

New study findings highlight the need for a rapid booster vaccine campaign to prevent COVID-19 caused by the Omicron variant since the neutralization of Omicron by the two-dose BNT162b2 vaccine is not effective in controlling the spread of the infection.

30 Dec 2021

Antibody News and Research

Further Reading

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

Production of molecular probes of spike and subdomains for all SARS-CoV-2 variants

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Minimal nAb titers against Omicron in the elderly after 3rd dose

SARS-CoV-2 Omicron study on hamsters, shows virus results in a less severe disease

NAbs activity against SARS-CoV-2 variants, including Omicron, in an elderly vaccinated cohort

Study shows structural and functional aspects of antibody neutralization of SARS-CoV-2 Omicron variant

TriSb92 as a potential inhibitor against SARS-CoV-2 variants including Omicron

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

Omicron infection induces cross-reactive immune responses

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

Vaccine-induced T-cells vs. Omicron well preserved compared with all variants

The use of monoclonal antibodies against infectious pathogens

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

Booster doses of mRNA vaccines improve humoral immunogenicity in patients with inflammatory bowel disease

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

BNT162b2 booster restores protection following waning of the 2-dose vaccine

Event guide: 5th Novel Conjugates Summit 2026 eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo